Angiochem Inc.

Angiochem Inc.

February 15, 2011 07:00 ET

Angiochem Receives Innovation Award From the National Brain Tumor Society for Advancing the Development of Novel Brain Cancer Treatments

EPiC Technology Platform Creates Anti-Cancer Compounds Crossing the Blood-Brain-Barrier Through LRP-1 Targeting

MONTREAL, CANADA, and WATERTOWN, MASSACHUSETTS--(Marketwire - Feb. 15, 2011) - Angiochem, Inc., a clinical stage biotechnology company, and the National Brain Tumor Society (NBTS), a leading U.S. non-profit organization in the brain tumor community, today announced that Angiochem has been presented with the Innovation Recognition Award from the National Brain Tumor Society for its progress in developing novel treatments for brain tumors that are capable of crossing the blood-brain barrier. The NBTS Innovation Recognition Award acknowledges catalytic research projects that will significantly move forward the field of brain tumor research.

Angiochem utilizes its proprietary platform for Engineered Peptide Compounds (EPiC) to discover and develop drugs that cross the blood-brain barrier through Low-Density Lipoprotein Receptor Related Protein-1 (LRP-1) targeting. Angiochem's most advanced product candidate, GRN1005 (formerly ANG1005), was recently licensed to Geron Corporation for the treatment of patients with primary and metastatic brain tumors.

"The blood-brain barrier is one of several factors that make brain tumors difficult to treat," said N. Paul TonThat, Executive Director of The National Brain Tumor Society. "For the hundreds of thousands of people in the U.S. who are living with or will be diagnosed with primary or metastatic brain tumors, the work being done by AngioChem represents a promising approach to overcoming one of those challenges by enabling drugs to cross the blood-brain barrier."

"We are honored to be acknowledged by the NBTS with this award, as we continue our mission of developing novel drugs to help patients for diseases with significant unmet needs, such as brain cancer" commented Jean-Paul Castaigne, MD, President and CEO of Angiochem. "Our EPiC platform technology has demonstrated the ability to penetrate brain tissue and, more importantly, brain tumors with compelling preliminary evidence of anti-tumor activity."

About the National Brain Tumor Society

National Brain Tumor Society is fiercely committed to improving the quality of life of all those affected by brain tumors. NBTS is dedicated to help: empower individuals with comprehensive information, online programs, caring support, and direct connections to others going through the same challenges; fund transformative research to lead more rapidly to new therapies for adult and pediatric brain tumors, and ultimately to cures; advocate for brain tumor patients, families, caregivers, healthcare professionals, and researchers.

About Angiochem

Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough drugs that are leveraging the LRP-1 mediated pathway to cross the blood-brain barrier (BBB) to treat brain diseases. These new Engineered Peptide Compounds (EPiC) have the potential to address significant medical needs, many of which cannot be effectively addressed due to the fundamental physiological challenge the blood-brain barrier presents for therapeutic intervention. Angiochem is developing a deep and broad product pipeline, including small molecules and biologics, for the potential treatment of a wide range of CNS diseases, including brain cancer, neurodegenerative and metabolic diseases, pain, and many others. Founded in 2003, Angiochem maintains headquarters in Montreal, Canada. For additional information about the Company, please visit http://www.angiochem.com.

Contact Information

  • Angiochem Contact:
    The Yates Network
    Gina Nugent
    617-460-3579
    or
    National Brain Tumor Society Contact:
    Lisa McEvoy
    617-924-9997 x1410